Perinatal Tissue-Derived Mesenchymal Stem Cell Business

「In December 2025, the company entered into a joint research agreement with the Department of Ophthalmology, School of Medicine, International University of Health and Welfare, and Eiwakai Medical Corporation to develop a new treatment for eye diseases using conditioned medium derived from umbilical cord mesenchymal cells. The study will assess its efficacy against corneal epithelial disorders and aims to obtain basic knowledge for future clinical applications.」

「For umbilical cords, the company launched a Family Conditioned Medium manufacturing service last June to produce conditioned medium containing growth factors that promote tissue regeneration and intercellular signaling substances such as exosomes for families that have stored their tissue. As a result, the percentage of cord blood customers who also store umbilical cords has risen to more than 50%.」

「In research and development using umbilical cords, the company established the Department of Musculoskeletal Sports Biomechanics with the Sports Medicine Department of the Graduate School of Medicine, Osaka University, during the period under review, and is advancing development of a new treatment for meniscal injuries. It is also advancing development of treatments for congenital diseases, including pediatric morphological abnormalities, with the Cell Processing and Transfusion Division of the Institute of Medical Science, The University of Tokyo, and the Tissue Engineering Division of the University of Tokyo Hospital.」

「The company continues to advance joint research with the Institute of Medical Science, The University of Tokyo, and the University of Tokyo Hospital to develop treatments using umbilical cords for congenital diseases, including pediatric morphological abnormalities, as well as joint research with the Graduate School of Medicine, Osaka University, to develop a new treatment for meniscal injuries using umbilical cords.」

「In April this year, based on the results of joint research with the Hospital of the Institute of Medical Science, The University of Tokyo, the company launched a new umbilical cord (navel cord) storage service.」

「Stem Cell Research Institute plans to launch Japan's first autologous umbilical cord storage service next fiscal year using technology from the Institute of Medical Science, The University of Tokyo. To accommodate an increase in the number of samples stored under this service and in future cord blood storage, the company is constructing a new CPC (cell processing center) in Yokohama, which is scheduled to begin operations at the start of next fiscal year.」

「In September, we began joint research with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital on congenital structural abnormalities, including cleft palate, esophageal atresia and abdominal wall defects, with the aim of realizing Japan’s first clinical application of cells derived from autologous umbilical cords.」

「The company is currently conducting joint research with the Hospital of the Institute of Medical Science, The University of Tokyo, on an autologous umbilical cord storage service, and is making the necessary preparations, including construction of a new CPC (cell processing center), to launch the business next year.」

「In addition to cord blood, the company is pursuing joint research with the Hospital of the Institute of Medical Science, The University of Tokyo, the Keio University School of Medicine and the Nihon University School of Medicine, among others, to develop new treatments and therapeutic drugs using perinatal tissues such as umbilical cords.」

「Meanwhile, joint research with the Hospital of the Institute of Medical Science, The University of Tokyo, on an autologous umbilical cord storage service is also making progress.」

「Meanwhile, with the aim of further expanding its business, the company is continuing joint research with the Hospital of the Institute of Medical Science, The University of Tokyo, toward what would be Japan's first autologous umbilical cord storage service and its clinical application.」

「In anticipation of future business expansion, the company began joint research in September this year with the Hospital of the Institute of Medical Science, The University of Tokyo, to establish a banking system for cells obtained from fetal appendages, including umbilical cords, and develop their clinical applications.」

「The company is also planning a new business involving mesenchymal stem cells derived from perinatal tissues, including umbilical cords, which have been attracting growing attention worldwide.」